Researchers scanned 5,000 proteins in single blood plasma samples taken from 16,894 participants to simultaneously capture the individualized imprints of current health status, and incident risk of cardiometabolic diseases such as diabetes, coronary heart disease, stroke,and heart failure.

Sponsored content brought to you by Cell Therapy Overview CAR-T therapies have quickly shifted the direction of treatments for aggressive diseases, such as blood cancers, where previous treatments were limited. There are currently over 1000 cell and gene therapy trials and two approved cell therapies, axicabtagene ciloleucel and tisagenlecleucel, but...

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.

Sponsored content brought to you by How Single-Cell Functional Proteomics Accelerates Immunotherapy Development: Opportunities from Pre-Clinical to Clinical Stages Many companies are racing to develop cancer immunotherapies--a market estimated to be worth $50 billion and expected to grow exponentially over the next several years. Some of the earliest such approved products...

Elysium Heath also announced Morgan Levine, Ph.D., of Yale School of Medicine has joined the company as head of bioinformatics to improve the testing methodology of Index, with the goal of making its application accurate and informative for individuals.

John Halamka, M.D., will oversee Mayo Clinic Platform as it carries out initial projects focused on home healthcare scheduling, patient data uploading, and supplying patient-specific treatment information based on Mayo Clinic data.

Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.

Researchers from the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and nine other centers, presented interim results at the American Society of Clinical Oncology Annual Meeting over the week showing demonstrating that pre-surgical neoadjuvant treatment of lung cancer patients with an immune checkpoint inhibitor was well-tolerated by patients and,...

Sponsored content brought to you by Checkpoint and Combination Therapy Overview Checkpoint immunotherapy development continues to grow at an incredible rate—as of 2018 there were more than 2250 clinical immunotherapy trials incorporating checkpoint therapy, with two of the three largest selling oncology drugs being checkpoint-based immunotherapies. As this field becomes even more...

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2)...